The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Dec. 22, 2015
Filed:
Jul. 16, 2012
Applicants:
J. Jeffry Howbert, Bellevue, WA (US);
Muralikrishna Duvvuri, Durham, NC (US);
Robert Hershberg, Seattle, WA (US);
Gregory Dietsch, Snohomish, WA (US);
Inventors:
J. Jeffry Howbert, Bellevue, WA (US);
Muralikrishna Duvvuri, Durham, NC (US);
Robert Hershberg, Seattle, WA (US);
Gregory Dietsch, Snohomish, WA (US);
Assignee:
VentiRx Pharmaceuticals, Inc., Seattle, WA (US);
Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C07D 223/16 (2006.01); C07D 227/10 (2006.01); A61K 31/55 (2006.01); A61K 31/724 (2006.01); A61K 9/00 (2006.01); A61K 9/08 (2006.01); A61K 9/19 (2006.01); A61K 47/48 (2006.01); B82Y 5/00 (2011.01); C08B 37/16 (2006.01);
U.S. Cl.
CPC ...
A61K 31/724 (2013.01); A61K 9/0019 (2013.01); A61K 9/08 (2013.01); A61K 9/19 (2013.01); A61K 31/55 (2013.01); A61K 47/48969 (2013.01); B82Y 5/00 (2013.01); C07D 223/16 (2013.01); C08B 37/0012 (2013.01);
Abstract
The present invention is directed generally to stable formulations of a TLR agonist preferably a TLR7 or a TLR8 agonist, for use in the treatment of cancer, preferably solid tumors and lymphomas. Specifically, the present invention is directed to stable formulations of up to 50 mg/ml of a TLR agonist which comprise a cyclodextrin.